These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35405268)

  • 1. Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis.
    Zhou W; Nie W; Wang Q; Shi W; Yang Y; Li Q; Zhu H; Liu Z; Ding Y; Lu Y; Chu N
    Int J Antimicrob Agents; 2022 Jun; 59(6):106589. PubMed ID: 35405268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
    Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis.
    Abdelwahab MT; Wasserman S; Brust JCM; Dheda K; Wiesner L; Gandhi NR; Warren RM; Sirgel FA; Meintjes G; Maartens G; Denti P
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0138121. PubMed ID: 34543098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.
    Millard J; Pertinez H; Bonnett L; Hodel EM; Dartois V; Johnson JL; Caws M; Tiberi S; Bolhuis M; Alffenaar JC; Davies G; Sloan DJ
    J Antimicrob Chemother; 2018 Jul; 73(7):1755-1762. PubMed ID: 29584861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment.
    Bolhuis MS; Akkerman OW; Sturkenboom MGG; Ghimire S; Srivastava S; Gumbo T; Alffenaar JC
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S327-S335. PubMed ID: 30496467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients.
    Alffenaar JW; van Altena R; Harmelink IM; Filguera P; Molenaar E; Wessels AM; van Soolingen D; Kosterink JG; Uges DR; van der Werf TS
    Clin Pharmacokinet; 2010 Aug; 49(8):559-65. PubMed ID: 20608757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.
    Al-Shaer MH; Märtson AG; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Houpt ER; Ashkin D; Griffith DE; Cegielski JP; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W; Changpradub D; Hemapanpairoa J; Thunyaharn S
    Infect Chemother; 2021 Sep; 53(3):503-511. PubMed ID: 34405596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
    Alghamdi WA; Alsultan A; Al-Shaer MH; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Schmidt S; Heysell SK; Kempker RR; Cegielski JP; Peloquin CA
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India.
    Resendiz-Galvan JE; Arora PR; Abdelwahab MT; Udwadia ZF; Rodrigues C; Gupta A; Denti P; Ashavaid TF; Tornheim JA
    Front Pharmacol; 2022; 13():1081123. PubMed ID: 36686664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection.
    Wasserman S; Denti P; Brust JCM; Abdelwahab M; Hlungulu S; Wiesner L; Norman J; Sirgel FA; Warren RM; Esmail A; Dheda K; Gandhi NR; Meintjes G; Maartens G
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients.
    Yang M; Zhao L; Wang X; Sun C; Gao H; Wang X; Qian S
    Antimicrob Agents Chemother; 2023 May; 95(5):. PubMed ID: 33558298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy.
    Ehmann L; Simon P; Busse D; Petroff D; Dorn C; Huisinga W; Dietrich A; Zeitlinger M; Wrigge H; Kloft C
    Clin Microbiol Infect; 2020 Sep; 26(9):1222-1228. PubMed ID: 32311473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating linezolid dose regimens against methicillin-resistant Staphylococcus aureus based on renal function in populations with different body weight.
    Zuo M; Sun Y; Zhao X; Xu G; Wang N; Chen J; Zhu L; Yang W; Zhao M
    J Clin Pharm Ther; 2022 Dec; 47(12):2162-2169. PubMed ID: 36053892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients.
    Dong H; Xie J; Chen L; Wang T; Sun J; Zhao Y; Dong Y
    Int J Infect Dis; 2014 May; 22():35-40. PubMed ID: 24603161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.